This Simple Rating Report Sets the Tone in Exelixis, Inc. (EXEL)

Analysts at Goldman, assumed coverage of Exelixis, Inc. (NASDAQ:EXEL) with Neutral recommendation, according to their opinion released on September 17. Analysts at Needham are sticking to their Buy recommendation. However, on May 11, they lifted target price for these shares to $30 from $33. Analysts at Needham, made their first call for the stock with a Buy rating, according to a research note that dated back to May 11.

Bears have made their way to Exelixis, Inc. (NASDAQ:EXEL) as short interest on EXEL stock has climbed by 930,964 shares during the most recent reporting period. The most recent short interest data has been released for the November 15th settlement date, which shows a increase in total short interest for EXEL, to 15,962,061, a surge of 6.19% since October 31st. Average daily volume for Exelixis, Inc. at the November 15th settlement jumped to 5,463,189, as compared to 3,923,581 at the October 31st report. That brought days to cover to 2.921748, a 23.73% decrease from the 3.830964 days to cover recorded at the prior short interest data release.

By watching the trading activity of corporate insiders, it will become easier to get a sense of Exelixis, Inc. (NASDAQ:EXEL)’s prospects. The earliest insider trade took place on 12/03/2018. Scangos George A parted with a total of 55 thousand shares of company at average share price of $20.84. The total for the sales was set at $1.15 million. After this transaction, the Director account balance stood at 1.48 million shares. The stock grew 1.25 percent since that insider sale. On 12/03/2018, Schwab Gisela, Pres, Prod Dev & Med Aff & CMO, sold 13.5 thousand shares at a price per share of $21.02. This removed 283.75 thousand shares from the insider’s fortune and the stock saw a 0.38 percent rally in value since the news became public. This transaction left 331.02 thousand shares in the Pres, Prod Dev & Med Aff & CMO account. On 11/30/2018, EVP and CFO Senner Christopher J. performed a sale transaction worth $173.18 thousand. This sale at $19.7 each has eliminated 8.79 thousand shares from the insider’s portfolio position. Meanwhile, shares have recorded 7.11 percent increase since the transaction was reported. The insider now is left with 149.3 thousand shares remaining in the account. Hessekiel Jeffrey, who performs the EVP and General Counsel job, sold 14.82 thousand shares for $285.25 thousand. The disposal occurred on 11/30/2018 was priced at $19.25 per share. The share price soared 9.61 percent since the reporting date. Hessekiel Jeffrey now left with a stake of 234.44 thousand EXEL stock worth $4.95 million after the insider selling.

Exelixis, Inc. (EXEL) is expected to jump by 35.36 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $40-month high price target. This represents a whopping 89.57 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $29, which represents a return potential of 37.44 percent when compared to the closing price of the stock of $21.1 on Thursday, December 06. The lowest price target for the stock is $19 — slightly more than -9.95 percent from EXEL’s current share price.

The shares are currently floating around the first support level of $20.16. Below this, the next support is placed in the zone of $19.23. Till the time, the EXEL stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 68.15 on daily chart, which may remain a cause for concern. If the price breaks below $19.23 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $21.57 mark may result into a pull-back move towards $22.05 level.

EXEL shares accumulated 0.54 points or 2.63 percent on Thursday to $21.1 with a heavy trade volume of 4.535 million shares. After opening the session at $20.16, the shares went as high as $21.11 and as low as $19.7, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $6.3 billion and now has 298.42 million shares outstanding. Exelixis, Inc. (EXEL) stock has gained 18.47 percent of market value in 21 trading days.

EXEL stock has a trailing 3-year beta of 2.26, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was $1.18 a share in the trailing twelve months. The stock’s value has fallen -30.59 percent year to date (YTD) against a decline of -21.06 percent in 12 month’s time. The company’s shares still trade -34.47 percent away from its 1-year high of $32.20 and 57.23 percent up from 52-week low of $13.42. The average consensus rating on the company is 2.1, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a sell.

Shares of Exelixis, Inc. (EXEL) are trading at a P/E ratio of 136.33 times earnings reported for the past 12 months. The industry EXEL operates in has an average P/E of 92.31. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 8.46 on the Price-to-Sales ratio. Compare this with the industry average P/S of 116.5. 96.9 percent is the gross profit margin for Exelixis, Inc. and operating margin sits at 49.4 percent. Along with this, the net profit margin is 49.5 percent.

EXEL will be showing off its Q4 earnings on March 04. Analysts are forecasting revenue to climb 59.6 percent to $192M in the next fiscal quarter, while earnings are seen soaring by nearly 100 percent to $0.24 per share. History has shown that shares in Exelixis, Inc. have gone down on 19 different earnings reaction days and are predicted to add 0.06 percent when the company reports upcoming earnings. In last reported earnings results, it earned $0.41 per share, better than the $0.19, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $225M, better than the $173M analysts expected. Earnings are estimated to increase by 276.4 percent this year, -1.86 percent next year and continue to increase by 46 percent annually for the next 5 years.